Stayble Therapeutics AB (OSTO:STABL) EBIT : kr-22.08 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB EBIT?

Stayble Therapeutics AB's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was kr-6.82 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was kr-22.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Stayble Therapeutics AB's annualized ROC % for the quarter that ended in Sep. 2023 was -322.07%. Stayble Therapeutics AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Stayble Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 163.51%.

Stayble Therapeutics AB EBIT Historical Data

The historical data trend for Stayble Therapeutics AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB EBIT Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-6.12

-6.87

-15.09

-12.03

-24.50

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-5.79	-4.88	-3.74	-6.65	-6.82

Competitive Comparison of Stayble Therapeutics AB's EBIT

For the Biotechnology subindustry, Stayble Therapeutics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's EV-to-EBIT falls into.

Stayble Therapeutics AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-22.08 Mil.

Stayble Therapeutics AB (OSTO:STABL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Stayble Therapeutics AB's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-27.444 * ( 1 - 0% )	/	( (8.315	+	8.727)	/ 2 )
=	-27.444	/	8.521
=	-322.07 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.032	-	0.678	-	( 25.603	-	max(0, 3.344	-	28.383	+	25.603	))
=	8.315

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.128	-	2.405	-	( 21.293	-	max(0, 5.482	-	23.478	+	21.293	))
=	8.727

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Stayble Therapeutics AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.26	/	( ( (0 + max(-3.317, 0))	+	(0 + max(-5.44, 0)) )	/	2 )
=	-27.26	/	( ( 0	+	0 )	/	2 )
=	-27.26	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.026999999999997)	-	(0.678	+	0	+	2.666)
=	-3.317

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.042000000000002)	-	(2.405	+	0	+	3.077)
=	-5.44

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Stayble Therapeutics AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-22.084	/	-13.506
	=	163.51 %

Stayble Therapeutics AB EBIT Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (OSTO:STABL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines